TouchLight

20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer to Expedite mRNA Vaccine Delivery Platform Program

Retrieved on: 
Wednesday, November 29, 2023
Commercialization, LNP, Sanofi, London Business School, Drug discovery, Messenger, Nuclear power plant, CEPI, JPMorgan Chase, Therapy, Duke University, University, Market access, TouchLight, Regulatory affairs, PNP, Publication, Infection, Vaccine

Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.

Key Points: 
  • Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.
  • Hugo Fry has 29 years of leadership experience in the pharmaceutical and biotechnology industry across multiple business models, therapeutic areas, and companies, including Sanofi.
  • Hugo has a strong and recent track record of business development and licensing deals in the pharma and biotech sectors.
  • +++ Meet the 20Med Therapeutics team in San Francisco during the JPMorgan week, January 8-12, 2024 to discuss partnering opportunities around our PNP mRNA vaccine delivery platform +++

Touchlight’s enzymatic doggybone DNA used in the manufacture of Versameb’s VMB-100 for first-in-human clinical study

Retrieved on: 
Tuesday, November 21, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Food and Drug Administration, Safety, DNA, GMP, Food, Gene, CDMO, Drug Master File, IND, Escherichia coli, SUI, FDA, DMF, Messenger, Therapy, Trial of the century, RNA, Vaccine, Pharmaceutical industry, TouchLight

This FDA clearance represents a further milestone for Touchlight’s enzymatic dbDNA and follows the prior announcement from February 2023 of the first client adopting dbDNA for clinical development in the US.

Key Points: 
  • This FDA clearance represents a further milestone for Touchlight’s enzymatic dbDNA and follows the prior announcement from February 2023 of the first client adopting dbDNA for clinical development in the US.
  • This IND marks the third product to enter clinical development using the dbDNA platform, further demonstrating its regulatory adoption in both the US and Europe.
  • Karen Fallen, CEO, Touchlight commented: “We would like to congratulate Versameb on this achievement and wish them success with their upcoming first-in-human study.
  • dbDNA is uniquely positioned for the rapid, synthetic, and scalable manufacture of GMP DNA using a small, simple footprint.

Curia expands biologics capabilities with access to Touchlight’s doggybone DNA

Retrieved on: 
Monday, July 24, 2023
DNA, Partnership, TouchLight, Protein, R&D, Cell, Messenger, Vaccine

ALBANY, N.Y. and HAMPTON, United Kingdom, July 24, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA).

Key Points: 
  • ALBANY, N.Y. and HAMPTON, United Kingdom, July 24, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA).
  • The arrangement expands Curia’s mRNA manufacturing offerings with an additional differentiated source of DNA raw material that is immediately available to be accessed by Curia customers.
  • “Curia remains committed to strengthening our biologics offerings and end-to-end mRNA manufacturing capabilities,” said Christopher Conway, President of R&D, Curia.
  • Touchlight’s enzymatic DNA is produced with a cell-free enzymatic process that offers unmatched benefits in speed, quality and capacity when compared to traditional plasmid DNA production.

Global Biologics Contract Development Market Report 2023: Sector is Expected to Reach $13.8 Billion by 2030 at a CAGR of 8.1% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 12, 2023
Health, Biotechnology, CDO, DNA, TouchLight, Drug development, Workflow, COVID-19, Cancer, Research, USD, Messenger, Organization, M&A, Growth, Pharmaceutical industry, Vaccine, Fine chemical, Pharma

The "Biologics Contract Development Market 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biologics Contract Development Market 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global biologics contract development market size is expected to reach USD 13.8 billion by 2030, expanding at 8.1% CAGR from 2023 to 2030, according to this report.
  • Key drivers attributed to the growth include rising adoption of advanced technologies by biologics manufacturers, M&A, and clinical trials in developing nations.
  • The market includes organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations.

Touchlight Completes Expansion, Creating One of the World’s Largest DNA Manufacturing Facilities in London, UK

Retrieved on: 
Wednesday, May 24, 2023
Biotechnology, Commercial Building & Real Estate, Manufacturing, Construction & Property, Health, Pharmaceutical, Biometrics, Other Science, Other Manufacturing, Genetics, Science, River Thames, GMP, DNA, US Foods, Drug Master File, Face, Big Pharma, Escherichia coli, Multimedia, Medicine, Research, AAV, Messenger, Government, Iron, Cholera, Engineering, FDA, IND, Gene, Pfizer, Fine chemical, Interior design, Vaccine, Pharmaceutical industry, TouchLight, S. J. Moreland and Sons

View the full release here: https://www.businesswire.com/news/home/20230523005900/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230523005900/en/
    Touchlight Completes Expansion, Creating One of the World’s Largest DNA Manufacturing Facilities in London, UK (Photo: Business Wire)
    The expanded state-of-the-art facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year.
  • Jonny Ohlson, Touchlight’s Executive Chair and Founder, said: “Touchlight has a long-held belief that scientists, like all creatives, function best in beautiful spaces.
  • The patented dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process.
  • The unique new 515m² facility now comprises 11 state-of-the-art good manufacturing practice (GMP) DNA manufacturing suites, bringing the total on site to 15, more than tripling the company’s DNA manufacturing capacity.

Touchlight Announces First FDA Clearance of an IND Utilising Doggybone DNA

Retrieved on: 
Tuesday, February 28, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, CDMO, DNA, Investigational New Drug, DMF, IND, GMP, Gene, AAV, Drug Master File, Messenger, Escherichia coli, Vaccine, TouchLight

Touchlight, a CDMO pioneering enzymatic DNA production to enable genetic medicines, today announced the first FDA clearance of an Investigational New Drug (IND) application in the US utilising doggybone DNA (dbDNA™).

Key Points: 
  • Touchlight, a CDMO pioneering enzymatic DNA production to enable genetic medicines, today announced the first FDA clearance of an Investigational New Drug (IND) application in the US utilising doggybone DNA (dbDNA™).
  • This is a further milestone for enzymatic DNA and follows the recent FDA acceptance of the Drug Master File (DMF) for GMP grade dbDNA.
  • This recent landmark represented a significant step towards regulatory adoption with dbDNA, which is recognised as the first enzymatic DNA platform with a DMF.
  • dbDNA is uniquely positioned for the rapid, synthetic, and scalable manufacture of GMP DNA using a small, simple footprint.

FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight’s Enzymatic doggybone DNA Technology

Retrieved on: 
Tuesday, January 24, 2023
Health, FDA, Genetics, Research, Science, Pharmaceutical, Biotechnology, DNA, QA, Messenger, Drug Master File, Therapy, Regulatory affairs, DMF, Gene, GMP, IND, Vaccine, TouchLight

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced a ground-breaking new milestone for its enzymatic doggybone DNA (dbDNA™), following the FDA acceptance of the Drug Master File (DMF) for GMP grade dbDNA.

Key Points: 
  • Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced a ground-breaking new milestone for its enzymatic doggybone DNA (dbDNA™), following the FDA acceptance of the Drug Master File (DMF) for GMP grade dbDNA.
  • This achievement marks the first time a DMF has been accepted for an enzymatically produced DNA platform, representing a sign of the growing interest and adoption of enzymatic DNA across the genetic medicine industry.
  • Touchlight’s dbDNA is a minimal, linear, double stranded, covalently closed DNA vector which is produced through an enzymatic manufacturing process as an alternative to bacterial derived plasmid DNA.
  • Touchlight’s doggybone DNA technology was utilised for the first time in human clinical studies in 2022, with multiple further studies initiating in 2023.

Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA

Retrieved on: 
Wednesday, December 7, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Biotechnology, Therapy, Immune system, API, MD, Immunotherapy, Patient, DNA, GMP, Neoplasm, RNA transfection, Trial of the century, Gene, Pharmaceutical industry, Medical imaging, Vaccine, TouchLight

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announces a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalised cancer immunotherapy.

Key Points: 
  • Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announces a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalised cancer immunotherapy.
  • Through the deal, Odimma will gain access to Touchlights proprietary doggybone DNA (dbDNA) vector technology, providing them with a clinical supply of personalised dbDNA, to support and underpin the development of their candidate immunotherapy cancer treatment.
  • Jean-Marc Limacher, MD, Chairman of Odimma Therapeutics said: The agreement between Odimma and Touchlight is an important step forward to secure Odimmas clinical development.
  • Touchlight DNA Services provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API.

Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform

Retrieved on: 
Tuesday, November 29, 2022
Other Manufacturing, Medical Devices, Genetics, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, General Health, API, DNA, Gene, Biotechnology, Bill, Nanoparticle, RNA transfection, Bill & Melinda Gates Foundation, CDMO, Safety, Vaccine, TouchLight

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform, financed by a new grant received from the Bill & Melinda Gates Foundation.

Key Points: 
  • Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform, financed by a new grant received from the Bill & Melinda Gates Foundation.
  • As part of the grant, Touchlight will also be investigating the performance of doggybone DNA for therapeutic monoclonal antibody production.
  • Karen Fallen, CEO of Touchlight, commented: This grant is further evidence of the potential of our doggybone DNA platform.
  • We are excited to start the program, which could potentially demonstrate that the doggybone DNA platform can support a rapid, scalable, durable and thermostable vaccine solution for future pandemic response.

Lonza and Touchlight collaborate on end-to-end mRNA offering

Retrieved on: 
Tuesday, September 6, 2022
CEO, Technology, RNA, Gene, Vaccine, Infection, TouchLight, API, DNA, GMP, CDMO, CHF, Biotechnology, Therapy, Plasmid, RNA transfection, CORE, Fine chemical

Access to this technology expands the options for Lonzas customers beyond the traditional method of working with plasmid DNA (pDNA), while continuing to benefit from the companys integrated mRNA manufacturing offering.

Key Points: 
  • Access to this technology expands the options for Lonzas customers beyond the traditional method of working with plasmid DNA (pDNA), while continuing to benefit from the companys integrated mRNA manufacturing offering.
  • Andr Goerke, Vice President, Business Unit Head mRNA, Lonza, commented: The strategic collaboration with Touchlight enables Lonza to further enhance its position as a global leader in mRNA manufacturing.
  • Karen Fallen, CEO, Touchlight DNA Services, added: We are delighted to provide Touchlight customers the benefits of an end-to-end mRNA offering through our collaboration with Lonza.
  • Lonza is the leading CDMO in mRNA manufacturing and has an established, global mRNA manufacturing network.